Fulminant aspergillosis of the nose and paranasal sinuses: a new clinical entity.
Fulminant aspergillosis of the nose and paranasal sinuses represents a new clinical entity occurring in individuals with depressed immunological responses. It is marked by a rapid malignant course, requiring early recognition, aggressive surgery and chemotherapy. Clinical manifestations include a rapidly progressive gangrenous mucoperiostitis advancing relentlessly to destruction of the nasal cavity and the paranasal sinuses within a few days. The recent emergence of this form of aspergillosis appears to be directly related to the increased intensity of chemotherapy and immunosuppression in the treatment of previously fatal neoplastic diseases. Control of this disease process requires aggressive therapy. This may include radical sinus ablation, debridement of nasal structures, chemotherapy and possible correction of immunological deficits, i.e., bone marrow transplantation. Four cases are discussed in detail to present the clinical spectrum of this new disease entity.
D000293:Adolescent; D001228:Aspergillosis / Q000175:diagnosis / Q000628:therapy; D002648:Child; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D008297:Male; D009668:Nose Diseases / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D012852:Sinusitis / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy